alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE>                                            9
<CIK>                         0000946453
<NAME>                        The Southern Banc Company, Inc.
<MULTIPLIER>                                   1,000
<CURRENCY>                                     U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                              JUN-30-1999
<PERIOD-START>                                 JUL-01-1998
<PERIOD-END>                                   JUN-30-1999
<EXCHANGE-RATE>                                1
<CASH>                                         1,380
<INT-BEARING-DEPOSITS>                         7,301
<FED-FUNDS-SOLD>                               0
<TRADING-ASSETS>                               0
<INVESTMENTS-HELD-FOR-SALE>                    21,350
<INVESTMENTS-CARRYING>                         23,707
<INVESTMENTS-MARKET>                           23,646
<LOANS>                                        42,207
<ALLOWANCE>                                    98
<TOTAL-ASSETS>                                 96,875
<DEPOSITS>                                     79,734
<SHORT-TERM>                                   0
<LIABILITIES-OTHER>                            496
<LONG-TERM>                                    0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       15
<OTHER-SE>                                     16,630
<TOTAL-LIABILITIES-AND-EQUITY>                 96,875
<INTEREST-LOAN>                                3,221
<INTEREST-INVEST>                              3,355
<INTEREST-OTHER>                               414
<INTEREST-TOTAL>                               6,990
<INTEREST-DEPOSIT>                             4,100
<INTEREST-EXPENSE>                             4,100
<INTEREST-INCOME-NET>                          2,890
<LOAN-LOSSES>                                  27
<SECURITIES-GAINS>                             33
<EXPENSE-OTHER>                                2,147
<INCOME-PRETAX>                                910
<INCOME-PRE-EXTRAORDINARY>                     910
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   598
<EPS-BASIC>                                  0.59
<EPS-DILUTED>                                  0.57
<YIELD-ACTUAL>                                 2.88
<LOANS-NON>                                    10
<LOANS-PAST>                                   0
<LOANS-TROUBLED>                               0
<LOANS-PROBLEM>                                0
<ALLOWANCE-OPEN>                               76
<CHARGE-OFFS>                                  5
<RECOVERIES>                                   0
<ALLOWANCE-CLOSE>                              98
<ALLOWANCE-DOMESTIC>                           98
<ALLOWANCE-FOREIGN>                            0
<ALLOWANCE-UNALLOCATED>                        0


</TABLE>
August 23 , 2016



### JUDGMENT



## The Fourteenth Court of Appeals

CARLOS GALLEGO S

- PIEDRA , Appellant

NO. 14

- 14

- 01027

- CR V.

THE STATE OF TEXAS , Appellee

________________________________ This cause was heard on the transcript of the record of the court below. Having considered the record, this Court holds that there was no error in the judgment. The Court orders the judgment AFFIRMED

.
We further order appellant pay all costs expended in t he appeal.

We further order this decision certified below for observance.
**Exhibit 32.1**

 

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

Inconnection with the Annual Report of LOUD Technologies Inc. (the “Company”) onForm 10-K for the period ended December 31, 2005 as filed with the Securitiesand Exchange Commission on the date hereof (the “Report”), we, James T. Engenand Timothy P. O’Neil, Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify,pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of theSarbanes-Oxley Act of 2002, that:

 

(1)  The Report fully complies with therequirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934;and

 

(2)  The information contained in the Report fairlypresents, in all material respects, the financial condition and result ofoperations of the Company.

 
| Dated:  March 31, 2006 | By:    |   /s/ James T.  Engen                                                            |   |
|------------------------|--------|---------------------------------------------------------------------------------------|--------|
|                   |   |   James T. Engen                                                                 |
|                   |   | *  Chairman,  President and Chief  Executive Officer*                       |
|                   |   |
|                   |   |
|                   |   | /s/ Timothy P. O’Neil                                                            |   |
|                   |   | Timothy  P. O’Neil                                                               |
|                   |   | *Chief Financial Officer, Senior Vice  President Finance, Secretary and*

*Treasurer* |
|                        |        |                                                                                       |        |  |

 

 

A signed original of this written statement requiredby Section 906 has been provided to LOUD Technologies Inc. and will be retainedby the Company and furnished to the Securities and Exchange Commission or itsstaff upon request.

 

----
EXHIBIT 32.1

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

In connection  with the  quarterly  report of Avitar,  Inc.  (the  "Company") on
Form10-QSB for the period ending  December 31, 2004 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Peter P. Phildius,
Chief Executive  Officer of the Company certify,  pursuant to 18 U.S.C.  Section
1350, as adopted pursuant to Section 906 of the  Sarbanes-Oxley  Act of 2002, to
my knowledge, that:

     (1) The Report  fully  complies  with the  requirements  of  Section  13(a)
or15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.

Date: February 14, 2005

                                                   /s/ Peter P. Phildius
                                                   ---------------------
                                                   Peter P. Phildius Chief
                                                   Executive Officer
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>                     <C>
<PERIOD-TYPE>                   3-MOS                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000             DEC-31-2000
<PERIOD-START>                             JUL-01-2000             JAN-01-2000
<PERIOD-END>                               SEP-30-2000             SEP-30-2000
<CASH>                                       1,339,915                       0
<SECURITIES>                                         0                       0
<RECEIVABLES>                                  279,280                       0
<ALLOWANCES>                                         0                       0
<INVENTORY>                                    576,324                       0
<CURRENT-ASSETS>                             2,210,424                       0
<PP&E>                                         106,682                       0
<DEPRECIATION>                                       0                       0
<TOTAL-ASSETS>                               2,339,703                       0
<CURRENT-LIABILITIES>                           62,995                       0
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       0
<COMMON>                                        34,009                       0
<OTHER-SE>                                   2,242,699                       0
<TOTAL-LIABILITY-AND-EQUITY>                 2,339,703                       0
<SALES>                                        233,007                 921,478
<TOTAL-REVENUES>                               233,007                 921,478
<CGS>                                          121,759                 405,115
<TOTAL-COSTS>                                  121,759                 405,115
<OTHER-EXPENSES>                               184,430                 586,565
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                   0                       0
<INCOME-PRETAX>                               (62,986)                (30,324)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                           (62,986)                (30,324)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                  (62,986)                (30,324)
<EPS-BASIC>                                      (.02)                   (.01)
<EPS-DILUTED>                                    (.02)                   (.01)


</TABLE>
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Implications of Automation and Other Technological Developments: A Selected Annotated Bibliography (1962)

              																	Alliston, James					 and 	Weinberg, Edgar. 						*Implications of Automation and Other Technological Developments: A Selected Annotated Bibliography (1962) : Bulletin of the United States Bureau of Labor Statistics, No. 1319*,												Washington, D.C: 								G.P.O., 										February 1962,									https://fraser.stlouisfed.org/title/4745,			accessed on September 26, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
<PAGE>   1
                                  June 18, 1999

Mosaix, Inc.
6464 185th Avenue NE
Redmond, Washington  98052

Ladies and Gentlemen:

        We have acted as counsel to you in connection with the proceedings for
the authorization and issuance by Mosaix, Inc. (the "Company") of up to
2,846,000 shares (the "Shares") of the Company's Common Stock, $.01 par value
per share (the "Common Stock") and the preparation and filing of a registration
statement on Form S-3 (the "Registration Statement") under the Securities Act of
1933, as amended (the "Securities Act"), which you are filing with the
Securities and Exchange Commission with respect to the Shares.

        We have examined the Registration Statement and such documents and
records of the Company and other documents as we have deemed necessary for the
purpose of this opinion. Based upon the foregoing, we are of the opinion that
upon the happening of the following events:

        (a)     the filing and effectiveness of the Registration Statement and
                any amendments thereto,

        (b)     due execution by the Company and registration by its registrar
                of the Shares,

        (c)     the offering and sale of the Shares as contemplated by the
                Registration Statement, and

        (d)     receipt by the Company of the consideration required for the
                Shares to be sold by the Company as contemplated by the
                Registration Statement,

the Shares will be duly authorized, validly issued, fully paid and
nonassessable.

        We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and any amendment thereto, including any and all
post-effective amendments and any registration statement relating to the same
offering that is to be


<PAGE>   2
June 18, 1999
Page 2


effective upon filing pursuant to Rule 462(b) under the
Securities Act, and to the reference to our firm in the Prospectus of the
Registration Statement under the heading "Validity of Common Stock". In giving
such consent, we do not thereby admit that we are in the category of persons
whose consent is required under Section 7 of the Securities Act.


                                Very truly yours,


                                /s/ Michael E. Stansbury
*Pursuant to 5

TH CIR. R. 47.5, the Court has determined that this opinion should not be

published and is not precedent except under the limited circumstances set forth in 5

TH CIR.

R. 47.5.4.

UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 97-40322

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

WILLIE PROBY, JR.,

Defendant-Appellant.

Appeal from the United States District Court

for the Eastern District of Texas

(3:96-CR-9-1)

September 16, 1998

Before POLITZ, Chief Judge, STEWART and PARKER, Circuit Judges.

PER CURIAM:*

Willie Proby, Jr., appeals from his conviction for possession with intent to

distribute cocaine base. Before entering a guilty plea Proby moved to suppress the

evidence secured by the officers’ warrantless search of his person and hotel room.

The trial court conducted a suppression hearing, including the testimony of Proby

and the police officers, and found that Proby had consented to the search by

gesturing for the officers to enter. The court denied Proby’s motion to suppress.
 

1 United States v. Cooper, 43 F.3d 140 (5th Cir. 1995).

 

2 United States v. Gonzales, 79 F.3d 413 (5th Cir. 1996).

 

3 Anderson v. City of Bessemer City, 470 U.S. 564 (1985).

2

Proby contends that the district court clearly erred in finding that he had

consented voluntarily, in finding that the search was within the scope of any such

consent, and in failing to determine whether the initial confrontation was

legitimate. We review the district court’s ruling on a motion to suppress after a

suppression hearing for clear error,1viewing the evidence in the light most

favorable to the prevailing party, except where such is inconsistent with the direct

trial court’sfindings or is clearly erroneousin light of the entire record as a whole.2

Our review of the entire record discloses no clear error in the findings of the

trial court.3 Further, under the circumstances of this case, we perceive no merit in

Proby’s contention that the district court erred in failing to specifically determine

whether the initial confrontation was legitimate.

The decision appealed is AFFIRMED.
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Report of the Committee on Federal Credit Programs to the President of the United States

              																	United States. Committee on Federal Credit Programs. 						*Report of the Committee on Federal Credit Programs to the President of the United States*,										February 11, 1963,									https://fraser.stlouisfed.org/title/1222,			accessed on September 25, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
§ 21.53 Notation and disclosure of disputed records. When an individual has filed a statement of disagreement under § 21.52(b)(2), the Food and Drug Administration shall: ( a ) Mark any portion of the record that is disputed to assure that the record will clearly show that portion is disputed whenever the record is disclosed.
( b ) In any subsequent disclosure under § 21.70 or § 21.71(a), provide a copy of the statement of disagreement and, if the Food and Drug Administration deems it appropriate, a concise statement of the agency's reasons for not making the amendment(s) requested. While the individual shall have access to any such statement, it shall not be subject to a request for amendment under § 21.50.
( c ) If an accounting was made under § 21.71(d) and (e) of a disclosure of the record under § 21.71(a), provide to all previous recipients of the record a copy of the statement of disagreement and the agency statement, if any.
§ 349.75 Labeling of ophthalmic vasoconstrictor drug products. ( a ) *Statement of identity.* The labeling of the product contains the established name of the drug(s), if any, and identifies the product as a “redness reliever” or “vasoconstrictor (redness reliever)” (select one of the following: “eye” or “ophthalmic”) “(insert dosage form, e.g., drops).”
( b ) *Indications.* The labeling of the product states, under the heading “Indications,” the following phrase: “Relieves redness of the eye due to minor eye irritations.”
( c ) *Warnings.* In addition to the warnings in § 349.50, the labeling of the product contains the following warnings under the heading “Warnings” for products containing any ingredient identified in § 349.18: ( 1 ) “If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.”
( 2 ) “Ask a doctor before use if you have [in bold type] narrow angle glaucoma.”
( 3 ) “Overuse of this product may produce increased redness of the eye.”
( 4 ) “If solution changes color or becomes cloudy, do not use.”
( 5 ) “When using this product [in bold type] pupils may become enlarged temporarily.”
( d ) *Directions.* The labeling of the product contains the following information under the heading “Directions”: Instill 1 to 2 drops in the affected eye(s) up to four times daily.
[53 FR 7090, Mar. 4, 1988, as amended at 65 FR 38428, June 21, 2000]
§ 520.1263b Lincomycin powder. ( a ) *Specifications.* Each gram of soluble powder contains lincomycin hydrochloride equivalent to 0.4 grams of lincomycin.
( b ) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter as follows: ( 1 ) Nos. 054771 and 061133 for use as in paragraph (d) of this section.
( 2 ) Nos. 016592 and 076475 for use as in paragraphs (d)(1) and (2) of this section.
( c ) *Tolerances.* See § 556.360 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Swine* — ( i ) *Amount.* 250 milligrams per gallon of drinking water to provide 3.8 milligrams per pound of body weight per day.
( ii ) *Indications for use.* For the treatment of swine dysentery (bloody scours).
( iii ) *Limitations.* Discard medicated drinking water if not used within 2 days. Prepare fresh stock solution daily. Do not use for more than 10 days. If clinical signs of disease have not improved within 6 days, discontinue treatment and reevaluate diagnosis. The safety of lincomycin has not been demonstrated in pregnant swine or swine intended for breeding. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Chickens* — ( i ) *Amount.* 64 milligrams per gallon of drinking water.
( ii ) *Indications for use.* For the control of necrotic enteritis caused by *Clostridium perfringens* susceptible to lincomycin in broiler chickens.
( iii ) *Limitations.* Discard medicated drinking water if not used within 2 days. Prepare fresh stock solution daily. Administer for 7 consecutive days. Do not allow rabbits, hamsters, guinea pigs, horses, or ruminants access to water containing lincomycin. Not for use in layer and breeder chickens. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 3 ) *Honey bees* — ( i ) *Amount.* Mix 100 milligrams lincomycin with 20 grams confectioners'/powdered sugar and dust over the top bars of the brood chamber once weekly for 3 weeks.
( ii ) *Indications for use.* For the control of American foulbrood (*Paenibacillus larvae*).
( iii ) *Limitations.* The drug should be fed early in the spring or late in the fall and consumed by the bees before the main honey flow begins to avoid contamination of production honey. Complete treatments at least 4 weeks before main honey flow. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[48 FR 3966, Jan. 28, 1983, as amended at 55 FR 3209, Jan. 31, 1990; 60 FR 14217, Mar. 16, 1995; 62 FR 65020, Dec. 10, 1997; 64 FR 13341, Mar. 18, 1999; 64 FR 13508, Mar. 19, 1999; 64 FR 66382, Nov. 26, 1999; 65 FR 10705, Feb. 29, 2000; 67 FR 17284, Apr. 10, 2002; 67 FR 71819, Dec. 3, 2002; 67 FR 78356, Dec. 24, 2002; 68 FR 3817, Jan. 27, 2003; 70 FR 1818, Jan. 11, 2005; 77 FR 20988, Apr. 9, 2012; 77 FR 29217, May 17, 2012; 78 FR 28823, May 20, 2014; 81 FR 22523, Apr. 18, 2016; 81 FR 94989, Dec. 27, 2016; 83 FR 48945, Sept. 28, 2018; 84 FR 8972, Mar. 13, 2019. Redesignated at 85 FR 18119, Apr. 1, 2020, as amended at 88 FR 16547, Mar. 20, 2023; 88 FR 84700, Dec. 6, 2023]